StockData
ALKSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Alkermes plc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026
$42.97+1.75 (+4.25%)

Close on Oct 19, 2026

Market cap
$7.45B
P/E (TTM)
113.1
Dividend yield
–

Alkermes plc. revenue by segment

By business segment

By product or service

RevenueQ2 26Q1 26Q4 25Q3 25Q2 25Q1 25Q4 24Q3 24Q2 24Q1 24Q4 23Q3 23% of revenueYoY
Product sales, net$411.72M$338.11M$315.49M$317.42M$307.24M$244.49M$307.73M$273.00M$269.27M$233.54M$241.97M$231.82M83.0%+34.0%
VIVITROL$124.45M$112.43M$124.13M$121.13M$121.66M$101.00M$134.13M$113.65M$111.87M$97.66M$102.38M$99.31M25.1%+2.3%
ARISTADA and ARISTADA INITIO$96.72M$93.82M$97.22M$98.05M$101.30M$73.48M$96.62M$84.65M$86.05M$78.87M$83.37M$81.83M19.5%-4.5%
LUMRYZ$96.57M$39.49M––––––––––19.5%–
LYBALVI$93.98M$92.36M$94.14M$98.25M$84.28M$70.02M$76.98M$74.70M$71.35M$57.01M$56.22M$50.68M18.9%+11.5%
Manufacturing and royalty revenues$84.29M$54.80M$69.06M$76.76M$83.42M$62.02M$122.26M$105.14M$129.86M$116.83M$135.50M$149.11M17.0%+1.0%
Royalty$63.38M$50.73M$65.74M$67.97M$66.86M$44.69M$69.09M$89.20M$109.58M$86.80M$103.96M$108.49M12.8%-5.2%
Manufacturing Revenue$20.90M$4.07M$3.31M$8.79M$16.57M$17.33M$53.17M$15.95M$20.28M$30.03M$31.54M$40.62M4.2%+26.2%
Research and development revenue–––$0$0$0$0$0$0$3.00K$3.00K$3.00K––

By region

From the segment and revenue-disaggregation notes of Alkermes's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.